PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12297313-0	2002	Glucose induced MAPK signalling influences NeuroD1-mediated activation and nuclear localization.	Glucose	0-7	neurogenic differentiation 1	Mus musculus	43-50	
12297313-2	2002	Here we show NeuroD1 is primarily cytoplasmic at non-stimulating glucose concentrations (i.e. 3 mM) in MIN6 beta-cells and nuclear under stimulating conditions (i.e. 20 mM).	Glucose	65-72	neurogenic differentiation 1	Mus musculus	13-20	
12297313-4	2002	Treatment with the MEK inhibitor PD98059 or substitution of a serine for an alanine at a potential mitogen-activated protein kinase phosphorylation site (S274) in NeuroD1 significantly increased the cytoplasmic level at 20 mM glucose.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	33-40	midkine	Mus musculus	19-22	
12297313-4	2002	Treatment with the MEK inhibitor PD98059 or substitution of a serine for an alanine at a potential mitogen-activated protein kinase phosphorylation site (S274) in NeuroD1 significantly increased the cytoplasmic level at 20 mM glucose.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	33-40	neurogenic differentiation 1	Mus musculus	163-170	
12297313-4	2002	Treatment with the MEK inhibitor PD98059 or substitution of a serine for an alanine at a potential mitogen-activated protein kinase phosphorylation site (S274) in NeuroD1 significantly increased the cytoplasmic level at 20 mM glucose.	Serine	62-68	neurogenic differentiation 1	Mus musculus	163-170	
12297313-4	2002	Treatment with the MEK inhibitor PD98059 or substitution of a serine for an alanine at a potential mitogen-activated protein kinase phosphorylation site (S274) in NeuroD1 significantly increased the cytoplasmic level at 20 mM glucose.	Alanine	76-83	neurogenic differentiation 1	Mus musculus	163-170	
12297313-4	2002	Treatment with the MEK inhibitor PD98059 or substitution of a serine for an alanine at a potential mitogen-activated protein kinase phosphorylation site (S274) in NeuroD1 significantly increased the cytoplasmic level at 20 mM glucose.	Glucose	226-233	midkine	Mus musculus	19-22	
12297313-4	2002	Treatment with the MEK inhibitor PD98059 or substitution of a serine for an alanine at a potential mitogen-activated protein kinase phosphorylation site (S274) in NeuroD1 significantly increased the cytoplasmic level at 20 mM glucose.	Glucose	226-233	neurogenic differentiation 1	Mus musculus	163-170	
12297313-5	2002	The rise in NeuroD1-mediated transcription in response to glucose also correlated with the change in sub-cellular localization, a response attenuated by PD98059.	Glucose	58-65	neurogenic differentiation 1	Mus musculus	12-19	
12297313-5	2002	The rise in NeuroD1-mediated transcription in response to glucose also correlated with the change in sub-cellular localization, a response attenuated by PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	153-160	neurogenic differentiation 1	Mus musculus	12-19	
12297313-6	2002	The data strongly suggest that glucose-stimulation of the MEK-ERK signalling pathway influences NeuroD1 activity at least partially through effects on sub-cellular localization.	Glucose	31-38	midkine	Mus musculus	58-61	
12297313-6	2002	The data strongly suggest that glucose-stimulation of the MEK-ERK signalling pathway influences NeuroD1 activity at least partially through effects on sub-cellular localization.	Glucose	31-38	neurogenic differentiation 1	Mus musculus	96-103